{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:13:51Z","timestamp":1791216831140,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,4,6]],"date-time":"2010-04-06T00:00:00Z","timestamp":1270512000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1038\/nrclinonc.2010.42","type":"journal-article","created":{"date-parts":[[2010,4,7]],"date-time":"2010-04-07T01:37:09Z","timestamp":1270604229000},"page":"277-288","source":"Crossref","is-referenced-by-count":155,"title":["Alterations in VHL as potential biomarkers in renal-cell carcinoma"],"prefix":"10.1038","volume":"7","author":[{"given":"Lucy","family":"Gossage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,6]]},"reference":[{"key":"BFnrclinonc201042_CR1","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc885","volume":"2","author":"WG Kaelin Jr.","year":"2002","unstructured":"Kaelin, W. G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673\u2013682 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc201042_CR2","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/qjmed\/77.2.1151","volume":"77","author":"ER Maher","year":"1990","unstructured":"Maher, E. R. et al. Clinical features and natural history of von Hippel\u2013Lindau disease. Q. J. Med. 77, 1151\u20131163 (1990).","journal-title":"Q. J. Med."},{"key":"BFnrclinonc201042_CR3","doi-asserted-by":"publisher","first-page":"10589","DOI":"10.1073\/pnas.93.20.10589","volume":"93","author":"JR Gnarra","year":"1996","unstructured":"Gnarra, J. R. et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl Acad. Sci. USA 93, 10589\u201310594 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201042_CR4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm0895-822","volume":"1","author":"O Iliopoulos","year":"1995","unstructured":"Iliopoulos, O., Kibel, A., Gray, S. & Kaelin, W. G. Jr. Tumor suppression by the human von Hippel\u2013Lindau gene product. Nat. Med. 1, 822\u2013826 (1995).","journal-title":"Nat. Med."},{"key":"BFnrclinonc201042_CR5","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1073\/pnas.95.15.8817","volume":"95","author":"A Schoenfeld","year":"1998","unstructured":"Schoenfeld, A., Davidowitz, E. J. & Burk, R. D. A second major native von Hippel\u2013Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl Acad. Sci. USA 95, 8817\u20138822 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201042_CR6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1128\/MCB.21.3.865-874.2001","volume":"21","author":"EJ Davidowitz","year":"2001","unstructured":"Davidowitz, E. J., Schoenfeld, A. R. & Burk, R. D. VHL induces renal cell differentiation and growth arrest through integration of cell\u2013cell and cell\u2013extracellular matrix signaling. Mol. Cell. Biol. 21, 865\u2013874 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrclinonc201042_CR7","first-page":"4957","volume":"58","author":"B Lieubeau-Teillet","year":"1998","unstructured":"Lieubeau-Teillet, B. et al. von Hippel\u2013Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res. 58, 4957\u20134962 (1998).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201042_CR8","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1073\/pnas.95.3.993","volume":"95","author":"A Pause","year":"1998","unstructured":"Pause, A., Lee, S., Lonergan, K. M. & Klausner, R. D. The von Hippel\u2013Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc. Natl Acad. Sci. USA 95, 993\u2013998 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201042_CR9","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1073\/pnas.68.4.820","volume":"68","author":"AG Knudson Jr.","year":"1971","unstructured":"Knudson, A. G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820\u2013823 (1971).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201042_CR10","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/hmg\/3.12.2169","volume":"3","author":"K Foster","year":"1994","unstructured":"Foster, K. et al. Somatic mutations of the von Hippel\u2013Lindau disease tumor suppressor gene in non-familial clear cell renal carcinoma. Hum. Mol. Genet. 3, 2169\u20132173 (1994).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrclinonc201042_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/ng0594-85","volume":"7","author":"JR Gnarra","year":"1994","unstructured":"Gnarra, J. R. et al. Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat. Genet. 7, 85\u201390 (1994).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201042_CR12","first-page":"2852","volume":"54","author":"T Shuin","year":"1994","unstructured":"Shuin, T. et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel\u2013Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 54, 2852\u20132855 (1994).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201042_CR13","first-page":"1092","volume":"55","author":"JM Whaley","year":"1994","unstructured":"Whaley, J. M. et al. Germ-line mutations in the von Hippel\u2013Lindau tumor-suppressor gene are similar to somatic von Hippel\u2013Lindau aberrations in sporadic renal cell carcinoma. Am. J. Hum. Genet. 55, 1092\u20131102 (1994).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrclinonc201042_CR14","doi-asserted-by":"publisher","first-page":"25733","DOI":"10.1074\/jbc.M002740200","volume":"275","author":"ME Cockman","year":"2000","unstructured":"Cockman, M. E. et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel\u2013Lindau tumor suppressor protein. J. Biol. Chem. 275, 25733\u201325741 (2000).","journal-title":"J. Biol. Chem."},{"key":"BFnrclinonc201042_CR15","doi-asserted-by":"publisher","first-page":"10430","DOI":"10.1073\/pnas.190332597","volume":"97","author":"T Kamura","year":"2000","unstructured":"Kamura, T. et al. Activation of HIF-1\u03b1 ubiquitination by a reconstituted von Hippel\u2013Lindau (VHL) tumor suppressor complex. Proc. Natl Acad. Sci. USA 97, 10430\u201310435 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201042_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell, P. H. et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271\u2013275 (1999).","journal-title":"Nature"},{"key":"BFnrclinonc201042_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/35017054","volume":"2","author":"M Ohh","year":"2000","unstructured":"Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel\u2013Lindau protein. Nat. Cell Biol. 2, 423\u2013427 (2000).","journal-title":"Nat. Cell Biol."},{"key":"BFnrclinonc201042_CR18","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1093\/emboj\/19.16.4298","volume":"19","author":"K Tanimoto","year":"2000","unstructured":"Tanimoto, K., Makino, Y., Pereira, T. & Poellinger, L. Mechanism of regulation of the hypoxia-inducible factor-1\u03b1 by the von Hippel\u2013Lindau tumor suppressor protein. EMBO J. 19, 4298\u20134309 (2000).","journal-title":"EMBO J."},{"key":"BFnrclinonc201042_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1101\/sqb.2005.70.001","volume":"70","author":"WG Kaelin","year":"2005","unstructured":"Kaelin, W. G. The von Hippel\u2013Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Cold Spring Harbor Symp. Quant. Biol. 70, 159\u2013166 (2005).","journal-title":"Cold Spring Harbor Symp. Quant. Biol."},{"key":"BFnrclinonc201042_CR20","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bbrc.2005.08.165","volume":"3","author":"WG Kaelin Jr.","year":"2005","unstructured":"Kaelin, W. G. Jr. The von Hippel\u2013Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem. Biophys. Res. Commun. 3 38, 627\u2013638 (2005).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrclinonc201042_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0076-6879(07)35019-2","volume":"43","author":"WG Kaelin Jr.","year":"2007","unstructured":"Kaelin, W. G. Jr. The von Hippel\u2013Lindau tumor suppressor protein: an update. Methods Enzymol. 43 5, 371\u2013383 (2007).","journal-title":"Methods Enzymol."},{"key":"BFnrclinonc201042_CR22","doi-asserted-by":"crossref","unstructured":"Kaelin, W. G. Jr. The von Hippel\u2013Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13 (Pt 2), 680s\u2013684s (2007).","DOI":"10.1158\/1078-0432.CCR-06-1865"},{"key":"BFnrclinonc201042_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc2502","volume":"8","author":"WG Kaelin Jr.","year":"2008","unstructured":"Kaelin, W. G. Jr. The von Hippel\u2013Lindau tumor suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer 8, 865\u2013873 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc201042_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev.pathol.2.010506.092049","volume":"2","author":"WG Kaelin","year":"2007","unstructured":"Kaelin, W. G. Von Hippel\u2013Lindau disease. Annu. Rev. Pathol. 2, 145\u2013173 (2007).","journal-title":"Annu. Rev. Pathol."},{"issue":"Pt 3","key":"BFnrclinonc201042_CR25","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1042\/BST0360472","volume":"36","author":"MJ Nyhan","year":"2008","unstructured":"Nyhan, M. J., O'Sullivan, G. C. & McKenna, S. L. Role of the VHL (von Hippel\u2013Lindau) gene in renal cancer: a multifunctional tumor suppressor. Biochem. Soc. Trans. 36 (Pt 3), 472\u2013478 (2008).","journal-title":"Biochem. Soc. Trans."},{"key":"BFnrclinonc201042_CR26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ceb.2007.10.001","volume":"19","author":"IJ Frew","year":"2007","unstructured":"Frew, I. J. & Krek, W. Multitasking by pVHL in tumor suppression. Curr. Opin. Cell Biol. 19, 685\u2013690 (2007).","journal-title":"Curr. Opin. Cell Biol."},{"key":"BFnrclinonc201042_CR27","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182\u20131186 (1971).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201042_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00018-005-5426-3","volume":"6","author":"S C\u00e9be-Suarez","year":"2006","unstructured":"C\u00e9be-Suarez, S., Zehnder-Fj\u00e4llman, A. & Ballmer-Hofer, K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell. Mol. Life Sci. 6 3, 601\u2013615 (2006).","journal-title":"Cell. Mol. Life Sci."},{"key":"BFnrclinonc201042_CR29","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/j.1464-410X.2009.08454.x","volume":"103","author":"L Bastien","year":"2009","unstructured":"Bastien, L. et al. Targeted therapies in metastatic renal cancer in 2009. BJU Int. 103, 1334\u20131342 (2009).","journal-title":"BJU Int."},{"issue":"Suppl.","key":"BFnrclinonc201042_CR30","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1002\/cncr.24229","volume":"115","author":"MB Atkins","year":"2009","unstructured":"Atkins, M. B. et al. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer 115 (Suppl.), 2247\u20132251 (2009).","journal-title":"Cancer"},{"issue":"Suppl.","key":"BFnrclinonc201042_CR31","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1002\/cncr.24232","volume":"115","author":"WG Kaelin Jr.","year":"2009","unstructured":"Kaelin, W. G. Jr. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 115 (Suppl.), 2262\u20132272 (2009).","journal-title":"Cancer"},{"key":"BFnrclinonc201042_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P. & Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289\u2013296 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201042_CR33","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783\u2013792 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201042_CR34","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","volume":"66","author":"A Lievre","year":"2006","unstructured":"Lievre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992\u20133995 (2006).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201042_CR35","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129\u20132139 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201042_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/humu.20385","volume":"28","author":"KR Ong","year":"2007","unstructured":"Ong, K. R. et al. Genotype\u2013phenotype correlations in von Hippel\u2013Lindau disease. Hum. Mutat. 28, 143\u2013149 (2007).","journal-title":"Hum. Mutat."},{"key":"BFnrclinonc201042_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/prot.22419","volume":"77","author":"JR Forman","year":"2009","unstructured":"Forman, J. R., Worth, C. L., Bickerton, G. R., Eisen, T. G. & Blundell, T. L. Structural bioinformatics mutation analysis reveals genotype\u2013phenotype correlations in von Hippel\u2013Lindau disease and suggests molecular mechanisms of tumorigenesis. Proteins 77, 84\u201396 (2009).","journal-title":"Proteins"},{"key":"BFnrclinonc201042_CR38","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/hmg\/10.10.1029","volume":"10","author":"SC Clifford","year":"2001","unstructured":"Clifford, S. C. et al. Contrasting effects on HIF-1\u03b1 regulation by disease-causing pVHL mutations correlate with patterns of tumorigenesis in von Hippel\u2013Lindau disease. Hum. Mol. Genet. 10, 1029\u20131038 (2001).","journal-title":"Hum. Mol. Genet."},{"issue":"Suppl. 1","key":"BFnrclinonc201042_CR39","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.3816\/CGC.2008.s.002","volume":"6","author":"AM Molina","year":"2008","unstructured":"Molina, A. M. & Motzer, R. J. Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. Clin. Genitourin. Cancer 6 (Suppl. 1), S7\u2013S13 (2008).","journal-title":"Clin. Genitourin. Cancer"},{"key":"BFnrclinonc201042_CR40","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/sj.onc.1209062","volume":"25","author":"K Knauth","year":"2006","unstructured":"Knauth, K., Bex, C., Jemth, P. & Buchberger, A. Renal cell carcinoma risk in type 2 von Hippel\u2013Lindau disease correlates with defects in pVHL stability and HIF-1\u03b1 interactions. Oncogene 25, 370\u2013377 (2006).","journal-title":"Oncogene"},{"key":"BFnrclinonc201042_CR41","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1128\/MCB.00282-07","volume":"27","author":"L Li","year":"2007","unstructured":"Li, L. et al. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol. Cell Biol. 27, 5381\u20135392 (2007).","journal-title":"Mol. Cell Biol."},{"key":"BFnrclinonc201042_CR42","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1182\/blood-2002-06-1843","volume":"101","author":"YD Pastore","year":"2003","unstructured":"Pastore, Y. D. et al. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 101, 1591\u20131595 (2003).","journal-title":"Blood"},{"key":"BFnrclinonc201042_CR43","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/ng1019","volume":"32","author":"SO Ang","year":"2002","unstructured":"Ang, S. O. et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat. Genet. 32, 614\u2013621 (2002).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201042_CR44","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-05-3074","volume":"66","author":"RE Banks","year":"2006","unstructured":"Banks, R. E. et al. Genetic and epigenetic analysis of von Hippel\u2013Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 66, 2000\u20132011 (2006).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201042_CR45","first-page":"1942","volume":"60","author":"H Brauch","year":"2000","unstructured":"Brauch, H. et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 60, 1942\u20131948 (2000).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201042_CR46","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.clon.2007.08.014","volume":"19","author":"JM Gim\u00e9nez-Bachs","year":"2007","unstructured":"Gim\u00e9nez-Bachs, J. M. et al. VHL protein alterations in sporadic renal cell carcinoma. Clin. Oncol. (R. Coll. Radiol.) 19, 784\u2013789 (2007).","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"BFnrclinonc201042_CR47","first-page":"859","volume":"13","author":"JH Kim","year":"2005","unstructured":"Kim, J. H. et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol. Rep. 13, 859\u2013864 (2005).","journal-title":"Oncol. Rep."},{"key":"BFnrclinonc201042_CR48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/gcc.10054","volume":"34","author":"K Kondo","year":"2002","unstructured":"Kondo, K. et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 34, 58\u201368 (2002).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFnrclinonc201042_CR49","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1038\/sj.onc.1204692","volume":"20","author":"X Ma","year":"2001","unstructured":"Ma, X., Yang, K., Lindblad, P., Egevad, L. & Hemminki, K. VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium. Oncogene 20, 5393\u20135400 (2001).","journal-title":"Oncogene"},{"key":"BFnrclinonc201042_CR50","doi-asserted-by":"publisher","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-07-4921","volume":"14","author":"ML Nickerson","year":"2008","unstructured":"Nickerson, M. L. et al. Improved identification of von Hippel\u2013Lindau gene alterations in clear cell renal tumors. Clin. Cancer Res. 14, 4726\u20134734 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201042_CR51","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ijc.23496","volume":"123","author":"JJ Patard","year":"2008","unstructured":"Patard, J. J. et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int. J. Cancer 123, 395\u2013400 (2008).","journal-title":"Int. J. Cancer"},{"key":"BFnrclinonc201042_CR52","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/path.1034","volume":"196","author":"P Schraml","year":"2002","unstructured":"Schraml, P. et al. VHL mutations and their correlation with tumor cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J. Pathol. 196, 186\u2013193 (2002).","journal-title":"J. Pathol."},{"key":"BFnrclinonc201042_CR53","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1158\/1078-0432.CCR-07-1753","volume":"14","author":"KM Smits","year":"2008","unstructured":"Smits, K. M. et al. Genetic and epigenetic alterations in the von Hippel\u2013Lindau gene: the influence on renal cancer prognosis. Clin. Cancer Res. 14, 782\u2013787 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201042_CR54","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000227697","volume":"5","author":"H Suzuki","year":"1997","unstructured":"Suzuki, H. et al. Mutational state of von Hippel\u2013Lindau and adenomatous polyposis coli genes in renal tumors. Oncology 5 4, 252\u2013257 (1997).","journal-title":"Oncology"},{"key":"BFnrclinonc201042_CR55","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2407-5-57","volume":"5","author":"KP van Houwelingen","year":"2005","unstructured":"van Houwelingen, K. P. et al. Prevalence of von Hippel\u2013Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer 5, 57 (2005).","journal-title":"BMC Cancer"},{"key":"BFnrclinonc201042_CR56","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/jnci\/94.20.1569","volume":"94","author":"M Yao","year":"2002","unstructured":"Yao, M. et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl Cancer Inst. 94, 1569\u20131575 (2002).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201042_CR57","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2214\/ajr.159.6.1442389","volume":"15","author":"PL Choyke","year":"1992","unstructured":"Choyke, P. L. et al. The natural history of renal lesions in von Hippel\u2013Lindau disease: a serial CT study in 28 patients. AJR Am. J. Roentgenol. 15 9, 1229\u20131234 (1992).","journal-title":"AJR Am. J. Roentgenol."},{"key":"BFnrclinonc201042_CR58","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S0022-5347(01)62509-6","volume":"160","author":"HP Neumann","year":"1998","unstructured":"Neumann, H. P. et al. Prevalence, morphology and biology of renal cell carcinoma in von Hippel\u2013Lindau disease compared to sporadic renal cell carcinoma. J. Urol. 160, 1248\u20131254 (1998).","journal-title":"J. Urol."},{"key":"BFnrclinonc201042_CR59","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/humu.20082","volume":"24","author":"C Gallou","year":"2004","unstructured":"Gallou, C. et al. Genotype\u2013phenotype correlation in von Hippel\u2013Lindau families with renal lesions. Hum. Mutat. 24, 215\u2013224 (2004).","journal-title":"Hum. Mutat."},{"key":"BFnrclinonc201042_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0304-3835(99)00031-2","volume":"141","author":"K Yang","year":"1999","unstructured":"Yang, K., Lindblad, P., Egevad, L. & Hemminki, K. Novel somatic mutations in the VHL gene in Swedish archived sporadic renal cell carcinomas. Cancer Lett. 141, 1\u20138 (1999).","journal-title":"Cancer Lett."},{"key":"BFnrclinonc201042_CR61","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ccr.2008.10.016","volume":"14","author":"JD Gordan","year":"2008","unstructured":"Gordan, J. D. et al. HIF-\u03b1 effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14, 435\u2013446 (2008).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201042_CR62","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.urolonc.2007.12.001","volume":"27","author":"MC Smaldone","year":"2009","unstructured":"Smaldone, M. C. & Maranchie, J. K. Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urol. Oncol. 27, 238\u2013245 (2009).","journal-title":"Urol. Oncol."},{"key":"BFnrclinonc201042_CR63","doi-asserted-by":"publisher","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","volume":"1","author":"K Kondo","year":"2003","unstructured":"Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF2\u03b1 is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, E83 (2003).","journal-title":"PLoS Biol."},{"key":"BFnrclinonc201042_CR64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1541-7786.89.2.2","volume":"2","author":"M Zimmer","year":"2004","unstructured":"Zimmer, M., Doucette, D., Siddiqui, N. & Iliopoulos, O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL\u2212\/\u2212 tumors. Mol. Cancer Res. 2, 89\u201395 (2004).","journal-title":"Mol. Cancer Res."},{"key":"BFnrclinonc201042_CR65","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S1535-6108(02)00043-0","volume":"1","author":"K Kondo","year":"2002","unstructured":"Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel\u2013Lindau protein. Cancer Cell 1, 237\u2013246 (2002).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201042_CR66","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1535-6108(02)00044-2","volume":"1","author":"JK Maranchie","year":"2002","unstructured":"Maranchie, J. K. et al. The contribution of VHL substrate binding and HIF-1\u03b1 to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247\u2013255 (2002).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201042_CR67","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/hmg\/10.10.1019","volume":"10","author":"MA Hoffman","year":"2001","unstructured":"Hoffman, M. A. et al. von Hippel\u2013Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10, 1019\u20131027 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrclinonc201042_CR68","doi-asserted-by":"publisher","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","volume":"23","author":"CJ Hu","year":"2003","unstructured":"Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B. & Simon, M. C. Differential roles of hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) and HIF-2\u03b1 in hypoxic gene regulation. Mol. Cell Biol. 23, 9361\u20139374 (2003).","journal-title":"Mol. Cell Biol."},{"key":"BFnrclinonc201042_CR69","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1128\/MCB.25.13.5675-5686.2005","volume":"25","author":"RR Raval","year":"2005","unstructured":"Raval, R. R. et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel\u2013Lindau-associated renal cell carcinoma. Mol. Cell Biol. 25, 5675\u20135686 (2005).","journal-title":"Mol. Cell Biol."},{"key":"BFnrclinonc201042_CR70","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.molcel.2008.12.004","volume":"32","author":"M Zimmer","year":"2008","unstructured":"Zimmer, M. et al. Small-molecule inhibitors of HIF-2\u03b1 translation link its 5'UTR iron-responsive element to oxygen sensing. Mol. Cell. 32, 838\u2013848 (2008).","journal-title":"Mol. Cell."},{"key":"BFnrclinonc201042_CR71","first-page":"802","volume":"9","author":"MH Bui","year":"2003","unstructured":"Bui, M. H. et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802\u2013811 (2003).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201042_CR72","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.juro.2008.05.015","volume":"180","author":"TK Choueiri","year":"2008","unstructured":"Choueiri, T. K. et al. von Hippel\u2013Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J. Urol. 180, 860\u2013866 (2008).","journal-title":"J. Urol."},{"key":"BFnrclinonc201042_CR73","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1464-410X.2006.06376.x","volume":"98","author":"BI Rini","year":"2006","unstructured":"Rini, B. I. et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and von Hippel\u2013Lindau gene status. BJU Int. 98, 756\u2013762 (2006).","journal-title":"BJU Int."},{"key":"BFnrclinonc201042_CR74","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11523-006-0039-9","volume":"2","author":"S Gad","year":"2007","unstructured":"Gad, S. et al. Somatic von Hippel\u2013-Lindau (VHL) gene analysis and clinical outcome under anti-angiogenic treatment in metastatic renal cell carcinoma: preliminary results. Targeted Oncology 2, 3\u20136 (2007).","journal-title":"Targeted Oncology"},{"issue":"Suppl.","key":"BFnrclinonc201042_CR75","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1200\/jco.2008.26.15_suppl.5046","volume":"26","author":"TE Hutson","year":"2008","unstructured":"Hutson, T. E. et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J. Clin. Oncol. 26 (Suppl.), 5046 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201042_CR76","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3816\/CGC.2007.n.020","volume":"5","author":"D Cho","year":"2007","unstructured":"Cho, D. et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 5, 379\u2013385 (2007).","journal-title":"Clin. Genitourin. Cancer"},{"key":"BFnrclinonc201042_CR77","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1158\/1078-0432.CCR-04-2019","volume":"11","author":"M Atkins","year":"2005","unstructured":"Atkins, M. et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11, 3714\u20133721 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201042_CR78","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1158\/0008-5472.CAN-09-0146","volume":"69","author":"R Beroukhim","year":"2009","unstructured":"Beroukhim, R. et al. Patterns of gene expression and copy-number alterations in von Hippel\u2013Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 69, 4674\u20134681 (2009).","journal-title":"Cancer Res."},{"issue":"Suppl. 3","key":"BFnrclinonc201042_CR79","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000088478","volume":"69","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet, P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (Suppl. 3), 4\u201310 (2005).","journal-title":"Oncology"},{"key":"BFnrclinonc201042_CR80","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1017\/S1462399409001173","volume":"11","author":"E Poon","year":"2009","unstructured":"Poon, E., Harris, A. L. & Ashcroft, M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev. Mol. Med. 11, e26 (2009).","journal-title":"Expert Rev. Mol. Med."},{"key":"BFnrclinonc201042_CR81","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.4161\/cc.8.9.8303","volume":"8","author":"MY Koh","year":"2009","unstructured":"Koh, M. Y. & Powis, G. HAF: the new player in oxygen-independent HIF-1\u03b1 degradation. Cell Cycle 8, 1359\u20131366 (2009).","journal-title":"Cell Cycle"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.42.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.42","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2010.42.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T15:49:34Z","timestamp":1711381774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2010.42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,6]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["BFnrclinonc201042"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2010.42","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,6]]}}}